Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives Average Rating of “Moderate Buy” from Brokerages

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has earned an average rating of “Moderate Buy” from the fourteen brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $187.71.

Several equities analysts have commented on the company. Morgan Stanley reaffirmed an “overweight” rating and issued a $183.00 price objective (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the company from $145.00 to $179.00 in a research report on Friday, March 7th. Truist Financial upped their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. Barclays reaffirmed an “overweight” rating and issued a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Finally, HC Wainwright upped their price objective on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a research report on Monday, March 10th.

Insider Buying and Selling

In related news, CAO Patricia Carr sold 1,140 shares of the company’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $137.81, for a total transaction of $157,103.40. Following the completion of the sale, the chief accounting officer now directly owns 7,012 shares in the company, valued at $966,323.72. This represents a 13.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CMO Robert Iannone sold 7,080 shares of the company’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the sale, the chief marketing officer now owns 82,024 shares of the company’s stock, valued at $11,368,526.40. This trade represents a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,736 shares of company stock worth $4,022,825 in the last three months. 4.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bessemer Group Inc. raised its stake in Jazz Pharmaceuticals by 0.3% in the fourth quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company’s stock valued at $3,317,000 after buying an additional 92 shares during the last quarter. CIBC Asset Management Inc raised its stake in Jazz Pharmaceuticals by 5.2% in the fourth quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock valued at $243,000 after buying an additional 97 shares during the last quarter. Synovus Financial Corp raised its stake in Jazz Pharmaceuticals by 0.5% in the fourth quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company’s stock valued at $2,365,000 after buying an additional 100 shares during the last quarter. Quarry LP raised its stake in Jazz Pharmaceuticals by 6.3% in the fourth quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $209,000 after buying an additional 100 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its stake in shares of Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after purchasing an additional 101 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $139.51 on Wednesday. The stock’s fifty day moving average is $130.22 and its two-hundred day moving average is $121.18. The company has a market capitalization of $8.47 billion, a PE ratio of 19.65, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $148.06.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.